Cano Health, Inc. CANO
Set alert
2.30 +2.30 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 12.43M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.08
- Beta
- 0.05
- Short ratio
- 2.03
- Inst. own
- 34.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 6, 2024
- 50-d avg
- 3.82
- 200-d avg
- 54.20
- 1y target
- 0.50
Analyst view
Consensus: hold
Hold
Price target (mean) 0.50
Recommendation trend
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -17.56 | -17.56 – -17.56 | -61.00 | +71.2% | 719.57M | +5.8% | 1 |
| Next quarter | -9.60 | -9.60 – -9.60 | -12.00 | +20.0% | 752.22M | -13.2% | 1 |
| Current year | -162.36 | -162.36 – -162.36 | -95.00 | -70.9% | 3.12B | +13.9% | 1 |
| Next year | -29.82 | -29.82 – -29.82 | -162.36 | +81.6% | 2.86B | -8.3% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2023 | Credit Suisse | Maintained | Neutral | Neutral |
| Aug 10, 2023 | Jefferies | Downgrade | Buy | Hold |
| Aug 10, 2023 | Citigroup | Downgrade | Buy | Neutral |
| May 15, 2023 | Piper Sandler | Maintained | Underweight | Underweight |
| May 11, 2023 | Credit Suisse | Reiterated | Neutral | Neutral |
| Jan 5, 2023 | UBS | Downgrade | Buy | Neutral |
| Jan 4, 2023 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Nov 15, 2022 | Citigroup | Maintained | — | Buy |
| Nov 9, 2022 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Nov 9, 2022 | Raymond James | Downgrade | Outperform | Market Perform |
| Oct 26, 2022 | Credit Suisse | Downgrade | Outperform | Neutral |
| Sep 6, 2022 | Truist Securities | Initiated | — | Hold |
| Aug 9, 2022 | Piper Sandler | Maintained | Underweight | Underweight |
| Jun 23, 2022 | Raymond James | Initiated | — | Outperform |
| Jun 14, 2022 | B of A Securities | Downgrade | Buy | Neutral |
| May 10, 2022 | Credit Suisse | Maintained | — | Outperform |
| May 10, 2022 | Piper Sandler | Maintained | — | Underweight |
| May 9, 2022 | Citigroup | Maintained | — | Buy |
| May 2, 2022 | B of A Securities | Initiated | — | Buy |
| Apr 19, 2022 | UBS | Initiated | — | Buy |
| Apr 5, 2022 | Piper Sandler | Downgrade | Neutral | Underweight |
| Mar 15, 2022 | Credit Suisse | Maintained | — | Outperform |
| Nov 9, 2021 | Piper Sandler | Maintained | Neutral | Neutral |
| Oct 19, 2021 | Jefferies | Initiated | — | Buy |
| Oct 18, 2021 | Piper Sandler | Initiated | — | Neutral |
| Sep 30, 2021 | Wolfe Research | Initiated | — | Outperform |
| Sep 20, 2021 | Citigroup | Initiated | — | Buy |
| Sep 9, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Aug 1, 2021 | Credit Suisse | Initiated | — | Outperform |